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The Marburg virus (MARV), an African filovirus closely related to the Ebola virus, causes a deadly hemorrhagic fever in humans, with up to
90% mortality. Currently, treatment of disease is only supportive, and no vaccines are available to prevent spread of MARV infections. In order to
address this need, we have developed and characterized a novel recombinant vaccine that utilizes a single complex adenovirus-vectored vaccine
(cAdVax) to overexpress a MARV glycoprotein (GP) fusion protein derived from the Musoke and Ci67 strains of MARV. Vaccination with the
cAdVaxM(fus) vaccine led to efficient production of MARV-specific antibodies in both mice and guinea pigs. Significantly, guinea pigs
vaccinated with at least 5 × 107 pfu of cAdVaxM(fus) vaccine were 100% protected against lethal challenges by the Musoke, Ci67 and Ravn
strains of MARV, making it a vaccine with trivalent protective efficacy. Therefore, the cAdVaxM(fus) vaccine serves as a promising vaccine
candidate to prevent and contain multi-strain infections by MARV.
© 2006 Elsevier Inc. All rights reserved.Keywords: Marburg virus; Vaccine; cAdVax; Glycoprotein; Challenge; Musoke; Ravn; Ci67Introduction
The two members of the virus family Filoviridae, Marburg
virus (MARV) and Ebola virus (EBOV), cause an acute
hemorrhagic fever with mortality rates of up to 90% in humans
(Huggins, 1997; Rollin et al., 2000). Recent outbreaks of MARV
occurred in the late 1990s in the Democratic Republic of Congo
and in 2004 in the Uige Province of Angola, making MARV a
matter of considerable public health concern and scientific interest
(Rodriguez, 2002; Sanchez et al., 2001). On November 7, 2005,
the latest outbreak was finally declared to be over by the Angolan
Ministry of Health (W.H.O., 2005b).With a total of 374 cases and
a nearly 90% mortality rate, the Angola outbreak became the
largest and deadliest outbreak of Marburg hemorrhagic fever on
record (Ndayimirije and Kindhauser, 2005; W.H.O., 2005a,b).⁎ Corresponding author. Fax: +1 843 884 0601.
E-mail address: dongj@genphar.com (J.Y. Dong).
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doi:10.1016/j.virol.2006.05.033Several strains of MARV have been identified, each with
antigenically distinct glycoprotein sequences. These MARV
strains include the Ci67 (Siegert et al., 1968) and Popp strains
(Bukreyev et al., 1995) (2 different strains isolated from the first
MARVoutbreak of 1967); the prototype Musoke strain from a
1980 case in Kenya (Smith et al., 1982); the Ravn strain from
the 1987 case in Kenya (Johnson et al., 1996); and the recently
isolated Angola strain from the latest outbreak which began in
2004 (C.D.C., 2005). The overall percentage nucleotide
difference in the GP gene coding regions between the Marburg
virus strains (except Angola which is still being characterized)
ranges from 0.1 to 21%, with the Ravn strain being the most
genetically distinct (Sanchez et al., 1998).
To date, there is no specific treatment for Marburg
hemorrhagic fever. Therefore, supportive therapy is the only
option for filovirus-infected patients. Previous approaches to
develop vaccines against MARV include killed/inactivated virus
preparations (Hevey et al., 1997, 2001; Ignatyev et al., 1996) and
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not only did these approaches provide only partial protection
against MARV challenges, but safety concerns also preclude
these traditional methods from being acceptable for human use. A
recombinant virus approach of utilizing benign or replication-
defective viruses to express antigenic proteins from the
pathogenic virus is being investigated by our group and others
to induce both humoral and cell-mediated immune responses
against MARV (Hevey et al., 1997, 1998, 2001; Jones et al.,
2005; Wang et al., 2006b). This approach appears to be a strategy
with a greater probability for achieving a vaccine that is both safe
and protective. Ideally, such a vaccine would not only protect
against a single strain of MARV but would cross-protect against
several MARV strains simultaneously. Marburg virus-like protein
(VLP) development is another promising approach being
investigated (Swenson et al., 2004; Warfield et al., 2003, 2004).
Previously, we have shown that incorporation of MARV
surface glycoprotein (GP) genes from the Ci67, Ravn and
Musoke strains into complex adenovirus-vectored vaccine
(cAdVax) designs induced potent humoral and cell-mediated
immune responses that were both specific to their respective
viral strains and cross-reactive to heterologous strains (Wang
et al., 2006b). GP is the only known viral protein exposed on the
surface of the virion and thus has been utilized by our group as
well as others as an antigen for eliciting both humoral and cell-
mediated immune responses (Hevey et al., 1997, 1998, 2001;
Jones et al., 2005; Riemenschneider et al., 2003; Wang et al.,
2006b). Expression of MARV GP either alone or in
combination with nucleoprotein (NP) has been shown to be
effective at inducing protective immunity against MARV
challenges in animal models (Hevey et al., 1997, 1998, 2001;
Jones et al., 2005; Riemenschneider et al., 2003).
Here, we describe a vaccine strategy that combines benign
infection by a cAdVax vaccine with the antigenic potential of a
MARV GP fusion protein. We hypothesized that expressing the
MARV GP from multiple MARV strains in a single cAdVax
vaccine would induce a multivalent immune response that is
protective against challenge by multiple MARV strains. To this
end, a GP fusion protein was developed by natural recombi-
nation events between multi-strain MARV GP gene sequences.
The resultant GP fusion was found to share 80–99% sequence
identity with the parental GP genes. When incorporated into a
cAdVax vaccine, the MARV vaccine candidate, known as
cAdVaxM(fus), induced specific antibody responses in both
mice and guinea pigs and protected guinea pigs from lethal
challenges by the Ci67, Musoke, and Ravn strains of MARV.
Results
Construction of a trivalent cAdVax-based vaccine
candidate—A complex adenovirus expression vector that
expresses a MARV GP fusion
Our cAdVax vaccine platform is based on a replication-
defective, complex adenovirus (Ad) vaccine vector that differs
from other Ad-based vectors in that it contains multiple deletions
within the AD serotype 5 (Ad5) E1, E3, and E4 (except openreading frame 6, E4ORF6) genes and multiple insertion sites in
the Ad genome. These modifications enable the vector to
accommodate relatively large amounts of exogenous DNA (up
to 7 kb) and render the vector deficient for replication.
1In order to develop a safe and effective trivalent MARV
vaccine, our plan was to construct a cAdVax vaccine containing
the Ci67 GP and Musoke NP genes on the left end of the vector
and the Musoke GP and Ravn GP on the right end of the genome.
However, we found that inclusion of the three GP gene sequences
(Ci67, Musoke, and Ravn) together in a single cAdVax construct
was genetically unstable and lead to recombination among the
three highly homologous gene sequences during large-scale
propagations of the vaccine. This was the case for the cAdVax
vaccine described here, as well as for other vaccine constructs in
development that included different genetic arrangements of the
MARV GP sequences within a single construct. We believe that
this may be the result of the high sequence identity among the
three strain GPs (78–94% sequence identity).
Interestingly, after sequencing analysis of the cAdVax
vaccine post-propagation, we found that the vector had retained
two human CMV promoters, each driving the expression of a
GP fusion gene, both of which were in-frame and nearly
identical (7 nucleotide sequence differences); however, the NP
sequence appeared to have been deleted during the recombina-
tion events. The two GP fusion genes appeared to be the result
of a series of recombination events that resulted in one copy of
the gene being located in the left end of the cAdVax vaccine,
with a second copy being located in the right end.
Following sequencing analysis, it was determined that the
first 138 bp of the 5′ N-terminus of both fusions were derived
from Ci67 GP while the remaining 1908 bp on the 3′ C-terminal
ends were derived from Musoke GP (GenBank accession
numbers DQ656106 and DQ656107). The resultant fusions are
in frame and have 99% identity to Musoke GP, 93% identity to
Ci67 GP, and 80% identity to Ravn GP at the nucleotide level.
Translation of the nucleotide sequences into amino acid
sequences revealed that the GP fusion peptide sequences have
99% identity to Musoke GP, 94% identity to Ci67 GP, and 78%
identity to Ravn GP (Fig. 1).
cAdVax-based Marburg vaccine efficiently overexpresses the
MARV GP fusion protein on the cell surfaces of
vector-transduced cells in vitro
Since the GP fusion gene sequence was in-frame and closely
resembled the Musoke GP sequence, it seemed likely that the
fusion protein would be expressed in a similar fashion to the
parental strain GPs. Cell surface expression of GP fusion
protein following cellular transduction by cAdVaxM(fus) would
suggest proper expression, folding, and localization of the
vaccine-induced GP fusion. In order to determine whether the
MARV GP fusion was being expressed and its relative cellular
localization, we conducted an immunofluorescence analysis
(IFA) as described in Fig. 2. HeLa cells transduced with
cAdVaxM(fus) in vitro demonstrated a staining pattern that is
typical of cell surface staining, suggesting the possible cell
surface expression of an antibody-reactive GP fusion protein. In
Fig. 1. Sequence comparison of the MARV GP fusion amino acid sequence with the parental MARV strains. The left and right end inserts of cAdVaxM(fus) were PCR
amplified and cloned into TOPO plasmid vectors and then sequenced as described in the Materials and methods. Nucleotide sequences (GenBank accession numbers
DQ656106 and DQ656107) were then converted to amino acid sequences, using Vector NTI, and compared. Left end fusion GP: peptide sequence of the GP fusion
that was inserted into the left end of the cAdVaxM(fus) vector; right end fusion GP: peptide sequence of the GP fusion that was inserted into the right end of the
cAdVaxM(fus) vector. Highlighted amino acids represent divergencies in the amino acid sequences.
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immunofluorescence staining.
Vaccination with the cAdVaxM(fus) vaccine induces
MARV-specific antibody responses in mice
We hypothesize that de novo synthesis of MARV GP antigen
would initiate an immune response similar to antigen
presentation by a cell actually infected with MARV, but without
the deleterious effects associated with an actual MARV
infection. Therefore, this would induce neutralizing responses
against naturally folded and glycosylated MARV GPs that are
nearly identical to those that would be produced by a native
MARV infection. While the GP fusion would be slightly
different from each of the original GPs, it is our belief that it
would still closely mimic native GP expression and therefore
have an advantage over recombinant GP preparations made in
bacteria or mammalian cell lines which would either have
alternative glycosylations or would have lost their natural
conformations during the extensive purification processes.
In order to determine whether the cAdVaxM(fus) vaccine
would be capable of inducing MARV-specific immuneFig. 2. High levels of MARV-GP antigens are detected on the cell surface following tra
were seeded in 24-well tissue culture plates. The next day, cells were transduced with
were washed and then probed with (A) polyclonal guinea pig anti-Ravn antibody,
antibody, followed by PE-labeled anti-mouse IgG; (C) pre-immune mouse serum, fol
primary antibody). As additional controls, cells were also infected with (E) Control A
(uninfected control). Panels E and F were both probed with anti-Ravn primary antibo
fluorescent microscope. Photomicrographs taken at 400× magnification.responses, we immunized CD-1 mice i.p. with 1 × 108 pfu of
cAdVaxM(fus) vaccine on weeks 0 and 8. Sera from vaccinated
mice were harvested on week 0 and every 6 weeks from weeks 2
to 26 for antibody analyses by ELISA against vaccine-
transduced cell lysates. A similar group of mice, immunized
with the same doses of a cAdVax-based dengue virus vaccine,
known as D1, served as a control (Fig. 3).
As demonstrated in Fig. 3, MARV GP-specific antibody
titers were induced following vaccination of mice with
cAdVaxM(fus) vaccine. Vaccinated mice generated antibodies
that bound specifically to the Ci67, Ravn, and Musoke strains of
MARV GP, with highest specificity for Ci67 GP. Surprisingly,
while the GP fusion was nearly identical in nucleotide and
amino acid sequence to Musoke GP, the mouse vaccinated sera
appeared to bind with least specificity to Musoke GP.
The cAdVaxM(fus) vaccine efficiently induces a humoral
immune response to MARV in guinea pigs
While the mouse antibody titers shown in Fig. 3 appeared
modest, vaccine-induced titers, particularly for Ci67,
showed sufficient promise to initiate characterization of thensduction with the cAdVaxM(fus) vaccine vector. HeLa cells (1 × 105 cells/well)
the trivalent cAdVaxM(fus) vaccine at an MOI of 5–10. 48 h post-infection, cells
followed by FITC-labeled anti-guinea pig IgG; (B) monoclonal anti-Musoke
lowed by PE-labeled anti-mouse IgG; or (D) FITC secondary antibody only (no
d vector, HC4, which expresses hepatitis C virus antigens only; or (F) No virus
dy followed by FITC-labeled secondary antibody. Cells were visualized under a
Fig. 4. Inoculation with cAdVaxM(fus) induces a dose-dependent Marburg-
specific humoral immune response in guinea pigs. Guinea pigs (18 animals per
group) were injected with 5 × 106, 5 × 107 or 5 × 108 pfu of cAdVax(fus) on day
0 and day 28 (week 4) and were bled 4 weeks after each inoculation. A control
group was immunized with 5 × 108 pfu of CHB1, a cAdVax-based vaccine
against hepatitis B virus. Sera were prepared and then assayed for antibody titer
by ELISA against MARV-Musoke inactivated virus. Serum from each animal
was analyzed individually. Statistically significant differences (P < 0.05) were
determined by using a one-tailed, paired t test. *Statistically significant
difference in anti-MARV (Musoke) antibody titers, compared to CHB1 control.
GMT, geometric mean titer.
Fig. 3. Inoculation with cAdVaxM(fus) induces Marburg GP-specific immune
responses in mice. CD-1 mice were vaccinated on weeks 0 and 8 by i.p. injection
with 1 × 108 pfu of cAdVaxM(fus) vaccine or D1, a control cAdVax vaccine
expressing antigens from dengue virus serotype 2. At week 0 and every 6 weeks
from weeks 2 to 26, sera were collected from four mice from each group. (A)
Anti-Ci67 GP titers; (B) anti-Ravn GP titers; (C) anti-Musoke GP titers. Arrows
indicate vaccination time points. Titers are presented as reciprocal dilution titers,
plotted on a log10 scale. cAdVaxM(fus) titers (filled circles) and control titers
(open circles) were assayed by ELISA (see Materials and methods). Longer
horizontal bars represent cAdVaxM(fus) average titers while shorter horizontal
bars represent control vaccine average titers. Serum from each animal was
analyzed individually. A one-tailed t test was conducted to compare vaccine
antibody titers to control titers; however, no statistical differences (P < 0.05)
were found.
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requires biosafety level 4 (BSL4) containment. In order to
evaluate protective immune responses, three groups of guinea
pigs were immunized with cAdVaxM(fus) vaccine at either5 × 106 pfu (low dose), 5 × 107 pfu (medium dose), or 5 × 108 pfu
(high dose) per animal. The control group was immunized with a
cAdVax-based hepatitis B vector vaccine, given at 5 × 108 pfu
per guinea pig. All guinea pigs were immunized at week 0, bled
and then boosted with a second dose of vaccine at week 4. At
8 weeks, they were bled again and then challenged with active
MARV viruses (see Fig. 4, Table 1). Sera were prepared and then
assayed for antibody titer by ELISA against MARV-Musoke
inactivated virus. As shown in Fig. 4, immunization with the
cAdVaxM(fus) vaccine resulted in significant humoral antibody
responses to MARV-Musoke. This response was dose-depen-
dent, reaching 3–4 log10 titers in animals receiving the two
higher vector doses.
The cAdVax-basedMARV fusion protein vaccine, cAdVaxM(fus),
protects guinea pigs from lethal challenge by three strains of
Marburg virus
Ideally, a promising vaccine candidate would be able to
induce an immune response that is sufficient to protect against
lethal challenge with multiple strains of MARV. To determine
whether inoculation with the cAdVaxM(fus) vaccine would be
protective against multi-strain infections, we conducted a
stringent challenge experiment on the same group of guinea
pigs described in Fig. 4. At 8 weeks following the primary
immunization (4 weeks from the boost), six guinea pigs from
each dosage group were challenged with Ci67, Musoke or Ravn
strain of MARV, given s.c. at 2000 times LD50 (lethal dose that
results in death in 50% of animals; Table 1). As shown in Table
1, the guinea pigs vaccinated with either the medium or high
dose cAdVaxM(fus) vaccine were 100% protected from the
lethal challenges by the Ci67, Musoke and Ravn strains of
MARV while all control animals died as a result of the MARV
Table 1
cAdVaxM(fus) vaccine protects guinea pigs from challenge at 2000 times the LD50 of three individual strains of MARV
Subgroup Vaccination (in 200 μl) Dose/Animal a Challenge b S/Tc % Survival
1 Trivalent 5 × 106 Ci67 6/6 100 Low dose group: 15/18 (S/T); 83.3% survival ⁎
2 Trivalent 5 × 106 Musoke 4/6 66.7
3 Trivalent 5 × 106 Ravn 5/6 83.3
4 Trivalent 5 × 107 Ci67 6/6 100 Medium dose group: 18/18 (S/T); 100% survival*
5 Trivalent 5 × 107 Musoke 6/6 100
6 Trivalent 5 × 107 Ravn 6/6 100
7 Trivalent 5 × 108 Ci67 6/6 100 High dose group: 18/18 (S/T); 100% survival*
8 Trivalent 5 × 108 Musoke 6/6 100
9 Trivalent 5 × 108 Ravn 6/6 100
10 Control 5 × 108 Ci67 0/6 0 Control group: 0/18 (S/T); 0% survival
11 Control 5 × 108 Musoke 0/6 0
12 Control 5 × 108 Ravn 0/6 0
a Three groups of 18 guinea pigs were vaccinated s.c. with either 5 × 106 pfu (low dose), 5 × 107 pfu (medium dose), or 5 × 108 pfu (high dose) of trivalent cAdVaxM
(fus) vaccine, administered in 200 μl volume per animal. The control group was immunized with 5 × 108 pfu of CHB1 control vaccine. All guinea pigs were
immunized at week 0, bled and then boosted with a second dose of vaccine at week 4.
b At 8 weeks, vaccinated guinea pigs were bled a second time and then challenged by s.c. injection with a single strain of active MARV virus (Ci67, Musoke, or
Ravn).
c S/T, survivors/total challenged with 2000 LD50 of Ci67, Musoke, or Ravn. The surviving guinea pigs were observed for at least 30 days after challenge, and
morbidity and mortality were recorded.
⁎ Statistically significant differences were determined using a Chi-squared distribution analysis. Survival rates for all doses of cAdVaxM(fus) vaccine were found to
be significant (P < 0.05).
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against Ci67 challenge at all vaccination doses tested.
Because each vaccination group was challenged with a
single strain of MARV (i.e., not sequentially “back-challenged”
with a second or third MARV strain), the trivalent protective
immune responses can be wholly attributed to the vaccine. In
contrast, if a single guinea pig group were vaccinated with
cAdVaxM(fus), challenged with Musoke, and then back-
challenged with Ci67, it would be unclear whether survival
from Ci67 challenge were due to protective immune responses
induced by the vaccine or by MARV-Musoke. These challenge
results, therefore, indicate a multivalent protective immune
response induced by the cAdVaxM(fus) vaccine.
Discussion
Currently there are no effective treatments for Marburg
hemorrhagic fever. In addition, no vaccines are available to
prevent the spread of infection once an outbreak has occurred.
While filovirus infections are rare and mainly occur in
Subsaharan Africa, the real threat is worldwide, considering
the highly contagious and deadly nature of these viruses and the
possibility that they may be exploited as biological weapons.
Given the nearly 90% mortality rate of the latest MARV
outbreak in Angola, it is important to develop vaccines against
these deadly viral agents to prevent future outbreaks.
In this study, we evaluate the first MARV vaccine to
demonstrate protection against challenges by the Musoke,
Ravn and Ci67 strains of MARV. Our approach differs from
other vaccine strategies, which are monovalent in design and
therefore express single antigens from only a single MARV
strain, usually the Musoke strain (Hevey et al., 1997, 1998, 2001;
Riemenschneider et al., 2003; Swenson et al., 2004; Warfield
et al., 2003, 2004). Among the many tested approaches in
developing MARV vaccines, vector-mediated antigen transfer,using either the Venezuelan equine encephalitis virus replicon
(Hevey et al., 1998, 2001) or a replication-competent vesicular
stomatitis virus (VSV) vector (Jones et al., 2005), appears to be
the most promising. Both vaccines have demonstrated protection
of non-human primates against MARV-Musoke challenges
(Hevey et al., 1998; Jones et al., 2005). However, one major
difficulty that remains in the development of an effective MARV
vaccine is the requirement for a multivalent capability to induce
protective immune responses against multiple MARV strains.
While the VSV-based vaccine was protective against
challenge with MARV-Musoke and then against back-challenge
with MARV-Popp (a strain very similar to Ci67) (Jones et al.,
2005), it is unclear whether survival from Popp challenge was
due to protective immune responses induced by the vaccine or
by the initial MARV-Musoke challenge. One would expect that
survival from challenge by one strain of MARV is likely to
induce strong immune responses against subsequent back-
challenge, especially if the back-challenge is with a genetically
similar strain (sequence identity between the Musoke and Popp
nucleotide sequences is 93.9%) (Bukreyev et al., 1995). The
hypothesis that Musoke virus challenge could be protective
against subsequent challenge with a different strain is clearly
demonstrated by Hevey et al., in which vaccination of guinea
pigs with the Musoke-derived GPΔTM baculovirus vector was
protective against Musoke but unprotective against Ravn.
However, vaccination with inactivated Musoke was 100%
protective against subsequent Ravn challenge (Hevey et al.,
1997).
In our studies, however, trivalent MARV protection can be
wholly attributed to the cAdVaxM(fus) vaccine because these
animals were each challenged with only a single strain of
MARV, with no back-challenges. Therefore, the cAdVaxM(fus)
vaccine truly demonstrated trivalent immune protection as the
vaccinated animals demonstrated 100% survival (at the high and
medium vaccine doses) when challenged with lethal doses of
330 D. Wang et al. / Virology 353 (2006) 324–332Musoke, Ravn or Ci67 viruses. Other current vaccine strategies
such as Marburg virus-like particles (VLPs) have also
demonstrated protective efficacy (Swenson et al., 2004;
Warfield et al., 2004), however, these particles are inefficient
to produce andwould require co-transfection of several plasmids
simultaneously to develop a trivalent vaccine approach.
Importantly, there is a distinct difference between our cAdVax-
based vaccines and those vaccines based on the first generationAd.
The major advantage of the cAdVax system over the first
generation Ad vector is the ability to express multiple antigens in
a single construct (up to six, depending on the sizes of the
respective antigens). Upon vaccination, all of the antigens carried
by the vector are produced at high levelswithin the cells transduced
at the vaccination site. We hypothesize that vector-based vaccine
gene transfer induces a de novo antigen synthesis, which results in
antigen expression and presentation on cell surfaces. This mimics a
natural infection by the pathogenic viruses and induces potent
immune responses without causing the disease.
To our knowledge, this is the first description in the literature of
a trivalentMARVvaccine shown to protect against multiple strain
infections of MARV. One of the major advantages of the trivalent
cAdVaxM(fus) vaccine is the fact that inoculation with a single
vaccine construct is sufficient to produce protective immunity to
three MARV strains. This, therefore, simplifies the production
and approval processes that would be necessary to bring this
trivalent vaccine to the public. In establishing a vaccine comprised
of a single vaccine vector, this decreases production costs and
FDA approval costs as well as ensures that there is no selective
expression of one strain antigen over other strain antigens.
Taken together, our data suggest that the trivalent cAdVaxM
(fus) vaccine represents a promising candidate for the
development of a broadly effective vaccine against MARV
infections. Importantly, the cAdVax vaccine demonstrated
efficient induction of a protective immune response, leading
to 83–100% efficacy in our guinea pig model. This protective
immunity is thought to be due to the humoral responses
generated in the guinea pigs. This is supported by recent
findings in a non-human primate model of Ebola in which
immune protection correlated well with GP-specific antibody
titers (Sullivan et al., 2006). The role of cell-mediated immunity
in protection is still uncertain, but quantitative measure of cell-
mediated activity does not appear to correlate with protection
(Sullivan et al., 2006). Additional studies will need to be
conducted to determine whether this is the case for the
cAdVaxM(fus) vaccine. However, it is clear that the cAd-
VaxM(fus) vaccine does demonstrate protective efficacy against
multivalent MARV strain challenges.
Materials and methods
Cell lines
HEK293 (human embryonic kidney), HeLa (human cervical
cancer) and BS-C-1 (African green monkey kidney) cell lines were
obtained from American Type Culture Collection (ATCC; Mana-
ssas, VA). All cell lines were maintained in DMEM supplemented
with 10% cosmic calf serum (CCS; HyClone; Logan, UT).Construction of the cAdVaxM(fus) vaccine
The Musoke GP (Genbank accession number Z12132), Ci67
GP (Genbank accession number AF005735), Ravn GP (Gen-
bank accession number AF005734), and Musoke NP (Genbank
accession number Z12132) genes were amplified by polymerase
chain reaction (PCR), with each primer including specific
restriction sites at the 5′ and 3′ ends for subsequent cloning of the
PCR fragments into pLAd or pRAd plasmid shuttle vectors. The
final PCR products were evaluated by sequencing analysis. The
cAdVaxM(fus) vaccine vector genome was constructed by
cloning the MARV GP and NP genes into pLAd and pRAd
shuttle vectors containing human cytomegalovirus intermediate/
early (CMV) promoters. These shuttle vectors were assembled
with an Ad5sub360-based backbone containing deletions in E3
and all E4 ORFs with the exception of ORF6 and were
assembled into a single linear vector genome as described
previously (Rubinchik et al., 2002, 2003). The GP fusion gene
sequence was generated by natural recombination events
between the Musoke, Ci67 and Ravn GP gene sequences that
occurred during the propagation of the vector (see Results).
Recombinant adenovirus vector propagation, confirmation,
and titer evaluation
All vectors were propagated in HEK293 cells, using standard
procedures (Rubinchik et al., 2001, 2002, 2003). Briefly,
HEK293 cells, which provide Ad5 E1a and E1b functions in
trans, were transfected with the recombinant cAdVax genomic
DNA using Lipofectamine™ Reagent following manufac-
turer's instructions (Invitrogen; Carlsbad, CA). Transfected
cells were maintained until Ad-related cytopathic effects (CPE)
were observed (typically 7–14 days post-transfection), at which
point the cells were collected.
After several rounds of single-plaque selection, candidate
vaccine clones were confirmed by restriction mapping digestion
as well as sequencing analysis of the virus DNA isolated from
positive cAdVax plaques to assure that the vaccine preparation
had no deletions or rearrangements. Vector transgenes were
completely sequenced including promoter regions with respect
to the insert sequences from pLAd and pRAd vaccine vectors
using Big Dye® Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) and the ABI 377 DNA
Sequencer (Applied Biosystems).
The final positive cAdVax clones were re-amplified in
HEK293 cells and purified by ultra-centrifugation in cesium
chloride gradients, as described previously (Rubinchik et al.,
2002, 2003; Wang et al., 2006a, 2006b). All vectors were
titrated on HEK293 cells infected in serial dilution on triplicate
columns of 12-well plates for particle forming units (pfu). The
resulting titers were scored as pfu/ml. The final vaccine was
confirmed again with restriction mapping digestion.
Sequencing of the cAdVaxM(fus) vaccine
Following analysis of the vaccine by restriction digestion,
viral DNA from the final preparation of cAdVaxM(fus) vaccine
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pLAd and pRAd insert sequences. PCR-amplified products
derived from the left and right ends of cAdVaxM(fus) were
cloned into the pCR®2.1-TOPO® Vector with the use of the
TOPO TA Cloning® Kit (Invitrogen). The resulting clones,
pM1LAd and pM1RAd, were sequenced as described above.
Full sequences for the pM1LAd and pM1RAd inserts were
obtained and manipulated within Vector NTI (Invitrogen) into
contigs which contained the entire regions corresponding to
MARV coding regions as well as the flanking sequences of the
vector. Flanking sequences matched exactly with the expected
vector regions; however, the MARV coding regions no longer
matched the expected cloned regions. The inserts themselves
were extremely homologous to one another, only differing by 7
nucleotides. These insert sequences both code for full-length, in-
frame glycoproteins that share an extremely similar identity.
Nucleotide comparison to each GP individually reveals that the
5′ ends of each inserts' ORFs match exactly with the sequence of
Ci67 GP. For both inserts, sequencing has indicated that the
restriction sites on the 5′ end of the insert correlate with the gene
construction method for Ci67. However, after a short stretch of
Ci67 homology, the inserts begin to match the sequence of
Musoke GP. This is first evident at nt 138 of each insert. Here, a
C in both inserts matches Musoke while the corresponding base
is a T in both Ci67 and Ravn. The inserts remain homologous
with Musoke for the remainder of their sequences (up to TAA
stop).
Immunofluorescence assay
HeLa cells (1 × 105 cells/well) were seeded in 24-well tissue
culture plates. The next day, cells were transduced by the
cAdVaxM(fus) vector at an MOI of 5–10. After 48 h post-
transduction, cells were washed with PBS containing 10% calf
serum and then incubated with either monoclonal anti-Musoke
or polyclonal guinea pig anti-Ravn antibodies at 1:20 dilution for
30 min at ambient temperature. Cells were washed twice with
PBS/10% serum to remove unbound primary antibodies. PE-
conjugated goat anti-mouse IgG (H + L) or FITC-conjugated
goat anti-guinea pig IgG (H + L) secondary antibodies (Jackson
ImmunoResearch Lab, Inc.; Bar Harbor, Maine) were added at a
1:100 dilution and incubated for 20 min. Following two more
washes with PBS/10% serum, cells were visualized under a
fluorescent microscope (LTP Inverted System Microscope,
IX70; Olympus Optical Co.; Tokyo, Japan) and photomicro-
graphs were taken.
Immunization of mice with cAdVaxM(fus) vaccine
6- to 8-week-old CD-1mice (Charles River,Wilmington,MA)
were immunized intraperitoneally (i.p.) with cAdVaxM(fus)
vaccine at 1 × 108 pfu/mouse on weeks 0 and 8. The control
group consisted of a similar group of mice immunized with the
same doses of an irrelevant cAdVax-based dengue virus (serotype
2) vaccine known as D1. Four mice from each group were
euthanized at week 0 and every 6 weeks from weeks 2 to 26. At
each time point, blood (via cardiac puncture) was harvested, andsera were prepared to determine the antibody titer. All mice were
maintained in accordance with Institutional Animal Care and Use
Committee-approved protocols. Each animal was analyzed
independently. Vaccinated mice were visually monitored for any
adverse effects resulting from immunization. Particular attention
was paid to food and water intake, coat texture (ruffled coats are
often a sign of illness), and excessive weight loss or gain.
Immunization and challenge of guinea pigs with cAdVaxM(fus)
vaccine
Three groups of 18 guinea pigs (maintained as a colony at
United States Army Medical Research Institute of Infectious
Diseases) were immunized subcutaneously with either
5 × 106 pfu, 5 × 107 pfu, or 5 × 108 pfu of cAdVaxM(fus)
vaccine administered at two dorsal sites at week 0 and week 4.
The control group consisted of 18 guinea pigs and received
control CHB1 vaccine (cAdVax expressing Hepatitis B
antigens) at 5 × 108 pfu per animal on weeks 0 and 4. Guinea
pigs were anesthetized, and blood was collected every 4 weeks,
just before inoculation and just before challenge. Six guinea pigs
per group were challenged subcutaneously with either Musoke,
Ravn or Ci67 strain of MARVat 2000 LD50 dose at week 8 from
the primary immunization. The surviving guinea pigs were
observed for at least 30 days after challenge, then anesthetized,
and exsanguinated. All work involving the handling of
filoviruses (i.e., immunization and challenge of guinea pigs,
guinea pig serum preparation, and guinea pig ELISA assays)
was conducted at the United States Army Medical Research
Institute of Infectious Diseases (USAMRIID) in their U.S.
government-approved BSL4 facilities.
Serum preparation
Sera were prepared from each blood sample by incubating the
blood at room temperature for approximately 4 h to allow for
clotting followed by an overnight incubation at 4 °C. The
following day, clots were removed by centrifuging blood at
2000 × g for 10 min. Supernatants were transferred to sterile
tubes and the serum stored at −80 °C. Small aliquots were stored
short-term at 4 °C. Sodium azide was added as a preservative to
these samples to a final concentration of 0.05%.
Mouse serum ELISA for Marburg GP antibodies
BS-C-1 cells were seeded in 100-mm plates. When cells
reached 80–90% confluency, they were infected with 2 ml each
of cAdVaxM(ci), cAdVaxM(ra), or cAdVaxM(mu) vaccine at
1 × 107 pfu/ml (MOI∼ 20). The cAdVaxM(ci) vaccine contains
2 copies of the Ci67 GP gene while the cAdVaxM(ra) and
cAdVaxM(mu) vaccines each encode 2 copies of the Ravn GP
and Musoke GP genes, respectively (Wang et al., 2006b). Three
days post-infection, cells were harvested using a cell scraper,
washed once in PBS and then lysed for 45 min at 4 °C in RSB-
NP40/PMSF buffer (10 mM Tris–Cl, pH 7.5, 10 mM NaCl,
1.5 mM MgCl2, 1% NP40, 1 mM PMSF). Lysed cells were
centrifuged at 15,000 × g for 5 min at 4 °C to remove solid
332 D. Wang et al. / Virology 353 (2006) 324–332cellular debris. Protein concentrations were quantified by a
modified Bradford Protein Assay according to manufacturers'
instructions (Advanced Protein Assay Reagent, Cytoskeleton,
Inc., Denver, CO). Flat-bottomed microtiter plates were coated
with cell lysates at 2.5 μg/ml for cAdVaxM(ci) and cAdVaxM
(mu) and at 20 μg/ml for cAdVaxM(ra). Coated plates were
blocked with 1% BSA in TBS/Tween. ELISA assays were
conducted as described previously (Wang et al., 2006a, 2006b).
Guinea Pig serum ELISA for Marburg antibodies
Guinea pig ELISA assays, using inactivated MARV-Musoke
as antigen target, were performed as previously described
(Hevey et al., 1997).
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